Publication & Citation Trends
Publications
0 total
1355 AGEN1721, a first-in-class Fc-enhanced bifunctional antibody targeting FAP and TGFβ, remodels the tumor microenvironment to overcome cancer-associated fibroblast-mediated immune suppression OA
Cited by 0
Semantic Scholar
720 Fc-enhanced anti-CTLA-4 antibody, botensilimabms, enhances the efficacy of multiple therapeutic modalities in immunotherapy-refractory tumor models OA
Cited by 0
Semantic Scholar
Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
Cited by 25
Semantic Scholar
Abstract 3915: BMS-986442 (AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity versus conventional anti-TIGIT antibodies in preclinical models
Cited by 1
Semantic Scholar
527 Preclinical dose-pharmacokinetic-efficacy modeling of botensilimab using a mouse surrogate of the Fc-enhanced anti-CTLA-4 antibody OA
Cited by 0
Semantic Scholar
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas.
Cited by 20
Semantic Scholar
A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.
Cited by 5
Semantic Scholar
470 Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumors OA
Cited by 9
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(47)
Monoclonal and Polyclonal Antibodies Research
(43)
Immunotherapy and Immune Responses
(21)
Peptidase Inhibition and Analysis
(14)
Immune Cell Function and Interaction
(13)
Affiliations
University of North Carolina at Chapel Hill
Agenus (United States)
Japan Science and Technology Agency
The University of Tokyo
Columbia University